XenTech
XenTech is a 20 years old CRO specialized in Patient-Derived Xenograft (PDX) models, a human tumor-based in vivo approach for accurate and highly predictive testing/profiling of many anti-cancer therapy modalities: ADCs, functional antibodies, immuno-therapeutics, PARPi and DDRi, TKIs,… .
Our portfolio includes acquired resistance models to benchmark ADCs. These models enable deeper investigation of resistance mechanisms and support the development of next-generation drug-conjugates strategies designed to overcome therapeutic escape.
The panel of 200+ deeply characterized models closely replicates the biological features of human tumors and covers the molecular diversity of clinical diseases for breast, prostate, lung, ovarian cancers and many other indications. All our studies are governed by a high-standard system of quality management and provide robust data for confident progression to clinical phases.
Xentech also proposes PDX Organoids and Derived cellular models derived from PDX in vivo models for in vitro testing of anti-cancer drug candidates.
